Get a detailed analysis on regions, market segments, customer landscape, and companies - View the snapshot of this report Forecast period 2024-2028 Base Year 2023 Historic Data 2018 - 2022 Segment Covered Product (Vaccination and Drug therapy), Type (Herpes zoster and Herpes simplex), and Geography (North America, Europe, Asia, and Rest of World (ROW)) Region Covered North America, Europe, Asia, and Rest of World (ROW) Key companies profiled AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc.
, Bausch Health Companies Inc., CENTURION REMEDIES Pvt. Ltd.
, Cipla Inc., Eli Lilly and Co., Fresenius SE and Co.
KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd.
, Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd.
, Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd.
, and Zydus Lifesciences Ltd. Key Market Trends Fueling Growth The herpes treatment market faces a significant reliance on a restricted range of therapies, primarily managing genital and oral herpes outbreaks without curing the disease. Research is ongoing to introduce innovative treatments, such as Genocea's GEN-003 vaccine, which controls both shedding and outbreaks of HSV-2 infection.
Clinical trials are underway for this therapeutic vaccine, which is effective only for those already infected. Prevention trials are also being considered. The emergence of these novel therapies will enhance the treatment landscape fo.